SCHEMBL1110285

SCHEMBL1110285

CCCCC(C(=O)O)N(c1ccc2cc(C(=O)NCC=O)ccc2c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR Q13258 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
CA2 P00918 2/20 0.33
PSEN1 P49768 2/20 0.33
PSEN2 P49810 2/20 0.33
APH1B Q8WW43 2/20 0.33
NCSTN Q92542 2/20 0.33
APH1A Q96BI3 2/20 0.33
PSENEN Q9NZ42 2/20 0.33
CA9 Q16790 3/20 0.32
CA1 P00915 2/20 0.32
CA12 O43570 2/20 0.32
GCGR P47871 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAPT P10636 2/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CCKBR P32239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110289 0.89 PSEN1 (0.38) PTGDRPTGDR2PSEN1PSEN2APH1B
SCHEMBL1110153 0.87 CA12 (0.46) CA9CA12ALDH1A1MAPTTP53
SCHEMBL1110381 0.85 RORC (0.37) CA2PSEN1PSEN2APH1BNCSTN
SCHEMBL1110347 0.83 MMP1 (0.36) CA2PSEN1PSEN2APH1BNCSTN
SCHEMBL1110298 0.81 MMP13 (0.36) CA2PSEN1PSEN2APH1BNCSTN
SCHEMBL4232855 0.79 KEAP1 (0.39) ALDH1A1L3MBTL1
SCHEMBL1110124 0.79 PSEN1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110182 0.78 PSEN1 (0.36) CA2PSEN1PSEN2APH1BNCSTN
SCHEMBL1110198 0.78 CYP3A4 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110232 0.78 CA12 (0.42) CA9CA1CA12ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 PTGDR 1160/4885PTGDR2 1207/4885CA2 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.